These results indicate that the combination of PI3Kβ/AKT inhibitors with a Mcl-1 inhibitor could be an effective therapeutic strategy to enhance treatment response and overcome mTORC1-driven acquired resistance to PI3K pathway inhibitors in PTEN-deficient breast cancer. The gene discussed is MCL1; the disease is breast cancer.